The current state of immunotherapy for gliomas: an eye toward the future.
Journal Article (Journal Article;Review)
The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.
Full Text
Duke Authors
Cited Authors
- Fecci, PE; Sampson, JH
Published Date
- September 1, 2019
Published In
Volume / Issue
- 131 / 3
Start / End Page
- 657 - 666
PubMed ID
- 31473668
Electronic International Standard Serial Number (EISSN)
- 1933-0693
Digital Object Identifier (DOI)
- 10.3171/2019.5.JNS181762
Language
- eng
Conference Location
- United States